Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States.
Xiaomeng YueYizhou YeYookyung C ChoiDongmu ZhangWhitney S KruegerPublished in: Advances in therapy (2022)
The risk of developing severe COVID-19 varied between the studied IMIDs and malignancies. Patients with hematologic cancers, solid tumors, or rheumatoid arthritis had significantly increased risk for severe COVID-19 compared to the general population. These findings highlight the need to protect and monitor immunocompromised patients such as those with IMIDs or malignancies as part of the strategy to control the pandemic worldwide.
Keyphrases
- coronavirus disease
- sars cov
- rheumatoid arthritis
- early onset
- end stage renal disease
- respiratory syndrome coronavirus
- ejection fraction
- newly diagnosed
- chronic kidney disease
- electronic health record
- type diabetes
- machine learning
- systemic lupus erythematosus
- big data
- interstitial lung disease
- intensive care unit
- systemic sclerosis
- skeletal muscle
- adipose tissue
- idiopathic pulmonary fibrosis
- extracorporeal membrane oxygenation